Brought to you by 
Merck gets rights to ImClone's cancer candidate
18 Oct 2007
Executive Summary
Merck KGAA acquired an exclusive license, outside North America, to develop and market ImClone Systems' lead anti-cancer compound, the IgG1 (immunoglobulin G1) C-225. In Japan, the two companies will co-develop and co-market the product. Merck does not get sublicense rights.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck gets rights to ImClone's cancer candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice